Treatment compliance (%)c Median (range) 95.6 (50–116) 97.6 (66–20.7) 97.5 (52–100) < 90% 12 (36.4) 9 (28.1) 2 (13.3) 90% 21 (63.6) 23 (71.9) 13 (86.7) ≥ aTime on treatment (weeks) = (last dosing date first dosing date + 1) / 7. bCumulative dose = sum of all actual (non-zero) daily doses received during the trial. – cTreatment compliance = (cumulative dose [mg] / planned cumulative dose [mg]) x 100%. Summary of TEAEs (safety analysis set) Table S3. Regimen 1 Regimen 2 Regimen 3 (n = 33) (n = 32) (n = 15) N (%) of patients with Any DLT 1 (3.0) 0 (0.0) 5 (33.3) At one TEAE 33 (100.0) 32 (100.0) 15 (100.0)
Treatment compliance (%)c Median (range) 95.6 (50–116) 97.6 (66–20.7) 97.5 (52–100) < 90% 12 (36.4) 9 (28.1) 2 (13.3) ≥ 90% 21 (63.6) 23 (71.9) 13 (86.7) aTime on treatment (weeks) = (last dosing date – first dosing date + 1) / 7. bCumulative dose = sum of all actual (non-zero) daily doses received during the trial. cTreatment compliance = (cumulative dose [mg] / planned cumulative dose [mg]) x 100%. Table S3. Summary of TEAEs (safety analysis set) Regimen 1 (n = 33) Regimen 2 (n = 32) Regimen 3 (n = 15) N (%) of patients with Any DLT 1 (3.0) 0 (0.0) 5 (33.3) At one TEAE 33 (100.0) 32 (100.0) 15 (100.0)
bcj2015103x1.docx